Advocacy Priorities

As part of The Arthritis Society’s advocacy program, The Society’s positions on issues affecting Canadians living with arthritis, advocacy guidelines and patient input submissions on pharmaceuticals are published here.

National Issues

Three national advocacy issues are prioritized for action:
Arthritis Research Funding
Income Supports
Primary Care

Provincial and Territorial Issues

Each divisional advocacy committee will identify the priority for action:
Juvenile Arthritis
Access to treatments
Supply/distribution of primary care professionals and specialists
Wait times and total joint replacement

Guidelines for advocacy relating to pharmaceuticals

The Arthritis Society should:
  • Make submissions, where relevant, to the Common Drug Review's newly established process for patient input and to similar provincial/territorial processes where these are instituted;
  • Where such a process does not exist or is not meaningful, advocate for the inclusion of a process for patient input as an integral part of the drug review process; and
  • Advocate for drug review processes at the federal, provincial and territorial levels that are relevant, timely and evidence-based.
The following principles will inform advocacy related to pharmaceuticals:
  • The Society will not advocate for any individual pharmaceutical, over-the-counter or therapeutic product; and
  • The Society's advocacy messages should reflect that:
    • There should be timely access to proven therapies that have been approved for use/marketing in Canada,
    • There should be maximum choice in therapies to allow each Canadian and their physicians to select the optimal treatment; and
    • Ability to pay should never create a barrier that prevents a Canadian from accessing the necessary therapies as prescribed by their physician.

Patient input submissions related to pharmaceuticals

All new drugs are submitted for review by the joint Federal/Provincial/Territorial (FPT) Common Drug Review (CDR) which makes recommendations for listing drugs that the federal, provincial and territorial drug plans then consider.  The CDR is a program of the Canadian Agency for Drugs and Technology in Health (CADTH), an independent, not-for-profit agency, funded by participating governments (all, except Quebec).  

CADTH has implemented a process by which patient groups would have input into drug review and decision-making around public drug plan formulary listings. The Arthritis Society develops these patient input submissions whenever a drug of interest to people living with arthritis is under consideration.
Current submissions
Previous submissions
Self advocacy toolkit

Self Advocacy Toolkit

Tools to help you advocate for yourself, a friend or loved one. Explore the Toolkit

Arthritis Research
Help Find a Cure

Help find a cure by supporting the best and brightest researchers who are investigating ways to prevent and treat arthritis.

Nikolas Harris
A Volunteer and Hero – Nik’s Story

I didn’t know what to expect... I left that first camp as a changed individual.

Impact Report 2015
Impact Report 2015

Read our 2015 Impact Report for stories of hope and how we support the 4.6 million Canadians living with arthritis.